We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.52%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$7.16B
AUM Growth
+$666M
(+10%)
Cap. Flow
+$831M
Cap. Flow
% of AUM
11.61%
Top 10 Holdings %
Top 10 Hldgs %
17.05%
Holding
983
New
189
Increased
207
Reduced
145
Closed
240
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$146M |
| 2 |
Gilead Sciences
GILD
|
+$116M |
| 3 |
Amazon
AMZN
|
+$86.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$84.7M |
| 5 |
Analog Devices
ADI
|
+$80M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$73.2M |
| 2 |
Palo Alto Networks
PANW
|
+$59.8M |
| 3 |
Alkermes
ALKS
|
+$55.3M |
| 4 |
Accenture
ACN
|
+$53.8M |
| 5 |
Johnson & Johnson
JNJ
|
+$53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.05% |
| 2 | Technology | 29.2% |
| 3 | Financials | 8.76% |
| 4 | Industrials | 7.7% |
| 5 | Communication Services | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CONX
251
DELISTED
CONX Corp. Class A Common Stock
CONX
| $6.5M | 0.09% |
650,000
+200,000
| +44% | +$1.99M |
|
252
Acadia Pharmaceuticals
ACAD
$4.96B
| $6.47M | 0.09% |
395,549
+135,582
| +52% | +$2.2M |
|
|
FRXB
253
DELISTED
Forest Road Acquisition Corp. II
FRXB
| $6.39M | 0.09% |
650,000
+150,000
| +30% | +$1.47M |
|
254
Chewy
CHWY
$9.7B
| $6.37M | 0.09% |
+207,465
| New | +$8.23M |
|
255
Ardelyx
ARDX
$1.22B
| $6.35M | 0.09% |
+5,339,065
| New | +$5.08M |
|
|
LATG
256
DELISTED
Chenghe Acquisition I Co. Class A Ordinary Shares
LATG
| $6.31M | 0.09% |
625,001
+25,001
| +4% | +$251K |
|
|
KNTE
257
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $6.27M | 0.09% |
524,669
+264,393
| +102% | +$3.46M |
|
|
KVSC
258
DELISTED
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
| $6.22M | 0.09% |
635,700
+416,700
| +190% | +$4.08M |
|
259
Larimar Therapeutics
LRMR
$435M
| $6.21M | 0.09% |
+1,941,739
| New | +$4.86M |
|
|
BPMC
260
DELISTED
Blueprint Medicines
BPMC
| $6.15M | 0.09% |
93,387
-22,700
| -20% | -$1.46M |
|
261
Appian
APPN
$2.2B
| $6.09M | 0.09% |
149,121
+25,397
| +21% | +$1.23M |
|
262
argenx
ARGX
$54.5B
| $6.08M | 0.09% |
17,236
-9,948
| -37% | -$3.69M |
|
|
KDNY
263
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $6.08M | 0.09% |
309,384
-91,639
| -23% | -$1.84M |
|
264
Viridian Therapeutics
VRDN
$2.45B
| $6.07M | 0.08% |
295,874
-256,497
| -46% | -$4.61M |
|
|
TWOA
265
DELISTED
two
TWOA
| $6.07M | 0.08% |
613,114
+313,114
| +104% | +$3.08M |
|
|
DOCU
266
DocuSign
DOCU
$10.8B
| $5.97M | 0.08% |
+111,604
| New | +$7M |
|
267
Elastic
ESTC
$7.18B
| $5.94M | 0.08% |
82,760
-492,099
| -86% | -$39.1M |
|
268
Spotify
SPOT
$98.4B
| $5.77M | 0.08% |
66,829
-45,195
| -40% | -$4.84M |
|
269
American Well
AMWL
$217M
| $5.74M | 0.08% |
79,915
+58,612
| +275% | +$5.13M |
|
270
MannKind Corp
MNKD
$1.22B
| $5.71M | 0.08% |
+1,849,389
| New | +$6.97M |
|
|
HTPA
271
DELISTED
Highland Transcend Partners I Corp.
HTPA
| $5.6M | 0.08% |
+562,500
| New | +$5.58M |
|
|
HAIA
272
DELISTED
Healthcare AI Acquisition Corp. Class A Ordinary Shares
HAIA
| $5.55M | 0.08% |
550,000
+250,000
| +83% | +$2.5M |
|
273
TG Therapeutics
TGTX
$7.66B
| $5.53M | 0.08% |
+934,436
| New | +$6.13M |
|
|
AFMD
274
DELISTED
Affimed
AFMD
| $5.42M | 0.08% |
263,169
+12,161
| +5% | +$338K |
|
275
Janux Therapeutics
JANX
$974M
| $5.42M | 0.08% |
400,181
+113,798
| +40% | +$1.52M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Woodline Partners held 983 positions worth $7.16B, up 10% from $6.49B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Woodline Partners deployed $831M of net new capital in Q3 2022, opening 189 new positions and adding to 207 existing holdings. Its largest new stake was Amazon: 683,398 shares worth $77.2M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $73.2M trimmed.
- Woodline Partners's largest Q3 2022 buy was Amazon: 683,398 shares worth $77.2M.
- Woodline Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $146M increase.
- Woodline Partners's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $73.2M.
- Woodline Partners fully exited Palo Alto Networks in Q3 2022, selling an estimated $59.8M.
- Woodline Partners's ten largest holdings make up 17% of its $7.16B portfolio in Q3 2022.
- Woodline Partners opened 189 new positions and closed 240 in Q3 2022.
- Woodline Partners's portfolio value rose 10% quarter-over-quarter to $7.16B.
Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.